Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether olokizumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · individuals with moderate or severe COVID‐19
1 finding from 1 review
Adverse events: all grades · individuals with moderate to severe disease
It is very uncertain whether summary of Findings Table ‐ Vitamin D changes adverse events (any grade) compared with placebo or standard care alone (very low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate to severe disease
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events (9 weeks) · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes total adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – nausea compared with morphine (very low certainty).
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – nausea compared with oxycodone (very low certainty).
1 finding from 1 review
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
1 finding from 1 review